Aromatase Inhibitor (AI)(Genentech, Inc.)은 Breast Cancer 표적 치료제로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 27% (ClinicalTrials.gov NCT01446159). 차별점: novel cell-free therapeutic paradigm, demonstrating that MSC-ApoVs mitigate hepatic fibrosis largely through the miR-409-3p-m.
Breast Cancer
Breast Cancer
Recruiting
CAR-T development and immunotherapy target identification
lipid nanoparticle (LNP) therapeutics
novel cell-free therapeutic paradigm, demonstrating that MSC-ApoVs mitigate hepatic fibrosis largely through the miR-409-3p-m
targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling
NK cell antibody-dependent cellular cytotoxicity
apoptosis of ES cells, upregulated expression of ligands to NK inhibitory receptors on ES cells, and enhanced mouse macrophage mi
biomarkers, enhanced trial matching, and scalable cohort identification
resistance to oncogene-targeted therapies remains incompletely defined
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Aromatase Inhibitor (AI)(Genentech, Inc.)은 Breast Cancer 표적 치료제로, Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 27% (ClinicalTrials.gov NCT01446159). 차별점: novel cell-free therapeutic paradigm, demonstrating that MSC-ApoVs mitigate hepatic fibrosis largely through the miR-409-3p-m.
Breast Cancer
Breast Cancer
Recruiting
CAR-T development and immunotherapy target identification
lipid nanoparticle (LNP) therapeutics
novel cell-free therapeutic paradigm, demonstrating that MSC-ApoVs mitigate hepatic fibrosis largely through the miR-409-3p-m
targeted and downregulated IGFBP3, thereby restricting the PI3K-AKT signaling
NK cell antibody-dependent cellular cytotoxicity
apoptosis of ES cells, upregulated expression of ligands to NK inhibitory receptors on ES cells, and enhanced mouse macrophage mi
biomarkers, enhanced trial matching, and scalable cohort identification
resistance to oncogene-targeted therapies remains incompletely defined
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.